We are pleased to announce Certara & Gilead are a 2023 Finalist in Excellence in use of Real-World Evidence
2022年11月3日 — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced that eight of the Company’s scientists have been featured in a list of the top 2% of scientists worldwide. The list was published in mid-October 2022 by Elsevier BV and Stanford University.
2022年11月2日 – Certara, Inc., the global leader in biosimulation, today announced that Amin Rostami, Ph.D and Geoff Tucker, Ph.D., co-founders of Simcyp (now, a division of Certara), have received the 2022 Innovation Award by the International Society of Pharmacometrics (ISoP) for their innovative contributions that have advanced/revolutionized the field of pharmacometrics and related scientific areas.
2022年10月19日 – Winners are recognized by agency and marketing peers for breakthroughs in pharmaceutical and healthcare marketing and communications.
2022年5月3日 — Certara, Inc., a global leader in biosimulation, today announced that the Company’s Simcyp COVID-19 Vaccine Model has been awarded a 2022 Bronze Edison Award in the Therapeutic Impact category.
2021年10月25日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced that its Simcyp COVID-19 Vaccine Model has won an R&D 100 Award, which recognizes the top 100 “R&D pioneers and their revolutionary ideas in science and technology” in the past year. The model, which is incorporated in Certara’s Vaccine Simulator, has been used by major pharmaceutical companies and allows researchers to study how a vaccine is handled by the human body in computer-generated, virtual populations.
2021年10月4日 – Certara, Inc., the global leader in biosimulation, today announced that Piet van der Graaf, Pharm.D., Ph.D,. is the recipient of the 2021 Leadership Award by the International Society of Pharmacometrics (ISoP) for his outstanding sustained leadership, mentorship, and contributions in the field of pharmacometrics.
